BMY vs ORGO · P/E 17, rev $24.46B vs rev $81.0M
Bristol-Myers Squibb Company (BMY) versus Organogenesis Holdings Inc (ORGO) — a side-by-side from cached financials, not a winner call.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Christopher S. Boerner Ph.D..
Organogenesis Holdings Inc (ORGO) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Latest reported ORGO revenue for 2026-06-30 was $81.0M. Net income was -$149.4M. ORGO currently screens at market cap $301.1M.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. ORGO currently screens at market cap $301.1M.
Not investment advice. Open the BMY and ORGO stock pages for the full models.
Not investment advice.